←
Nuvalent328 posts
Nuvalent avatar

Nuvalent

@nuvalent

Creating #preciselytargetedtherapies for patients with cancer, designed to overcome limitations of existing therapies for clinically proven kinase targets

◷ Joined January 2021▧ 293 Photos and videos
Nuvalent avatar
Nuvalent@nuvalent·Jul 15

Today, Nuvalent officially becomes part of GSK. Building on our legacy of strong science and commitment to patients, we look forward to continuing to advance innovative, precisely targeted medicines for people living with cancer, together. Learn more: gsk.to/3T1uzts

Nuvalent avatar
Nuvalent@nuvalent·Jul 14

Oncology care is a coordinated effort built on expertise, communication, and trust, with patients and clinicians partnering in informed decision-making. Gail’s advice reminds us of the importance of leaning on your care team for support as you navigate your treatment journey.

0:08
Nuvalent avatar
Nuvalent@nuvalent·Jun 30

Last week, some of our #NuCrew colleagues laced up their running shoes and took on the Boston @jpmorgan Corporate Challenge! Teamwork, fresh air, and skyline views made for a great evening celebrating connection beyond our desks. Proud of all who ran and cheered!

0:05
Nuvalent avatar
Nuvalent@nuvalent·Jun 29

This year’s 20th Annual Bio-Ball tournament was a SLAM DUNK! 🏀🔥 Unforgettable moments with the @SpOlympicsMA athletes and the #NuCrew. We are proud to support an organization that promotes inclusion, empowerment, and the power of sport!

0:06
Nuvalent avatar
Nuvalent@nuvalent·Jun 26

Advocacy can help drive meaningful change for patients with ALK+ #LungCancer. Empower yourself and ensure your voice is heard with a tailored care plan. Explore our doctor discussion guide and other patient resources at elevatelungcancercare.com/AL…

0:13
GSK avatar
⟳ Nuvalent retweeted
GSK@GSK·Jun 9

#News for #investors and #media: We have entered an agreement to acquire clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio. Find out more: gsk.to/4ooHOjy

0:07
Nuvalent avatar
Nuvalent@nuvalent·Jun 8

That’s a wrap on the 2026 @ASCO Annual Meeting. The #NuCrew had a great time connecting with the #oncology community and presenting clinical updates from our #ALK+ #NSCLC and #ROS1+ programs. Thanks to all who joined for our oral presentation and stopped by our poster. #ASCO26

Post attachment
Nuvalent avatar
Nuvalent@nuvalent·May 27

Additionally, we are pleased to welcome Georg Pirmin Meyer, M.D. as Chief International Officer to lead our international expansion strategy. Learn more here: investors.nuvalent.com/2026-…

Nuvalent avatar
Nuvalent@nuvalent·May 27

We are excited to share that the FDA has accepted for filing with Priority Review our NDA for neladalkib, our investigational ALK-selective inhibitor in TKI pre-treated advanced ALK-positive #NSCLC with a PDUFA date of November 27, 2026.

0:38
Nuvalent avatar
Nuvalent@nuvalent·May 7

This morning, we reported our Q1 2026 financial results, along with recent pipeline and business progress and anticipated milestones. Learn more here. investors.nuvalent.com/2026-…

0:30